Dendritic Cell Cancer Vaccines Market By Product Type (CreaVax, Sipuleucel-T (Provenge), Others), By End User (Pediatrics, Adults), By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2017–2022)
Dendritic Cell Cancer Vaccines Market By Product Type (CreaVax, Sipuleucel-T (Provenge), Others), By End User (Pediatrics, Adults), By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2017–2022)
ID: 5452 | Pages: 175 | December 2017 | Region: Global
The Global Dendritic Cell Cancer Vaccines market size was around USD XX billion in 2017. It is expected to grow at a CAGR of XX% to reach USD XX billion by 2022.
Leukocytes of a very rare kind are termed as Dendritic cells (DCs). They are highly effective in providing antigens to T cells. If kept isolated and administered tumour antigen ex vivo then DCs if administered as a cellular vaccine are found to enhance immunity in animals. They are found in lymphoid organs. Enhancement in immunity comes from the secretion of cytokines. As of now cancer treatment relies heavily on radiation, chemo etc. DCs are adaptable and hence provide flexibility in treatment of different kinds of cancer.
Increasing number of cases of people suffering from cancer, better availability of treatment methods, rising healthcare expenditure, savoury government policies and heavy investments in R&D, and improving success rates of clinical trials are the primary factors driving the growth of this market. Augmenting geriatric population, rapid advancements in technology and the ability to combat several cancer antigens are the secondary factors fuelling market growth.
Little or no penetration of DC vaccines in remote areas, strict administrative and regulatory frameworks, and ambiguity over the results of the clinical trials on these vaccines are the primary restraints of market growth.
The market is segmented by end user and product type. Classification by end user entails paediatrics and adults. Classification by product type entails CreaVax, Sipuleucel-T (Provenge), and others. Provenge was the first DC vaccine which was introduced in the market. So naturally it follows that it is the market leader and is expected to remain so till the end of the forecast period. It treats melanoma, prostate cancer etc. It was approved by the FDA nearly seven years ago.
Classification by geography entails North America, Latin America, Europe, Asia Pacific and Middle East and Africa. North America captured highest market share. US lead the market in this region. Europe is not far behind and is expected to close in on the North American market in the aforementioned forecast period. UK is the market leader in this region. Asia Pacific will continue its high growth spurt till 2022. Booming economies of India and China are spearheading this spectacular growth. Latin America and MEA continue to lag and will remain the least attractive markets all through the forecast period.
Key players in the market include 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 CreaVax
5.1.3 Sipuleucel-T (Provenge)
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 End User
5.2.1 Introduction
5.2.2 Pediatrics
5.2.3 Adults
5.2.4 Y-o-Y Growth Analysis, By End User
5.2.5 Market Attractiveness Analysis, By End User
5.2.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By End User
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 3M Company
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Activarti
8.3 Argos Therapeutics
8.4 Batavia Bioservices
8.5 Bellicum Pharmaceuticals
8.6 Creagene
8.7 DanDrit Biotech
8.8 DCPrime
8.9 Sanpower Corporation (Dendreon Corporation)
8.10 Elios Therapeutics
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
- Segment-level analysis in terms product type market size forecasts and estimations to detect key areas of industry growth in detail
- Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
- Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
- Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
- A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
- Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
- An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
- Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
| Title | Price | Add To Cart |
- Global Dendritic Cell Cancer Vaccines Market By Region, From 2016-2022 ( USD Million )
- Global Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Global CreaVax Market By Region, From 2016-2022 ( USD Million )
- Global Sipuleucel-T (Provenge) Market By Region, From 2016-2022 ( USD Million )
- Global Others Market By Region, From 2016-2022 ( USD Million )
- Global Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Global Pediatrics Market By Region, From 2016-2022 ( USD Million )
- Global Adults Market By Region, From 2016-2022 ( USD Million )
- North America Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- North America CreaVax Market By Region, From 2016-2022 ( USD Million )
- North America Sipuleucel-T (Provenge) Market By Region, From 2016-2022 ( USD Million )
- North America Others Market By Region, From 2016-2022 ( USD Million )
- North America Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- North America Pediatrics Market By Region, From 2016-2022 ( USD Million )
- North America Adults Market By Region, From 2016-2022 ( USD Million )
- United States Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- United States Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Canada Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Canada Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Europe Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Europe CreaVax Market By Region, From 2016-2022 ( USD Million )
- Europe Sipuleucel-T (Provenge) Market By Region, From 2016-2022 ( USD Million )
- Europe Others Market By Region, From 2016-2022 ( USD Million )
- Europe Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Europe Pediatrics Market By Region, From 2016-2022 ( USD Million )
- Europe Adults Market By Region, From 2016-2022 ( USD Million )
- U.K. Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- U.K. Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Germany Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Germany Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- France Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- France Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Italy Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Italy Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Spain Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Spain Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Asia Pacific Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Asia Pacific CreaVax Market By Region, From 2016-2022 ( USD Million )
- Asia Pacific Sipuleucel-T (Provenge) Market By Region, From 2016-2022 ( USD Million )
- Asia Pacific Others Market By Region, From 2016-2022 ( USD Million )
- Asia Pacific Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Asia Pacific Pediatrics Market By Region, From 2016-2022 ( USD Million )
- Asia Pacific Adults Market By Region, From 2016-2022 ( USD Million )
- Japan Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Japan Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- China Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- China Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- India Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- India Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Australia Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Australia Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- South Korea Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- South Korea Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Latin America Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Latin America CreaVax Market By Region, From 2016-2022 ( USD Million )
- Latin America Sipuleucel-T (Provenge) Market By Region, From 2016-2022 ( USD Million )
- Latin America Others Market By Region, From 2016-2022 ( USD Million )
- Latin America Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Latin America Pediatrics Market By Region, From 2016-2022 ( USD Million )
- Latin America Adults Market By Region, From 2016-2022 ( USD Million )
- Brazil Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Brazil Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Argentina Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Argentina Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Mexico Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Mexico Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Rest of Latin America Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Rest of Latin America Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Middle East and Africa Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Middle East and Africa CreaVax Market By Region, From 2016-2022 ( USD Million )
- Middle East and Africa Sipuleucel-T (Provenge) Market By Region, From 2016-2022 ( USD Million )
- Middle East and Africa Others Market By Region, From 2016-2022 ( USD Million )
- Middle East and Africa Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Middle East and Africa Pediatrics Market By Region, From 2016-2022 ( USD Million )
- Middle East and Africa Adults Market By Region, From 2016-2022 ( USD Million )
- Middle East Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Middle East Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
- Africa Dendritic Cell Cancer Vaccines Market By Product Type, From 2016-2022 ( USD Million )
- Africa Dendritic Cell Cancer Vaccines Market By End User, From 2016-2022 ( USD Million )
Licence Type 
Clients
Why buy reports from Market Data Forecast
Free Customization
Free report customization that helps you gain required information for always being one step ahead of the competition
Post Purchase Support
6 months of post purchase support via email and phone; serving your needs 24x7 and helping you troubleshoot any technical issues
Best Price guaranteed
Customer focused research services and expertly devised strategic analyses made into premium quality reports at lowest prices
Insightful Snapshots
Summarized overviews of entire reports into customized presentations to ascertain market estimations and driving forces at a quick glance